combination with individually dose adapted interleukin 2 (IL-2) treatment under taurolidine protection and locoregional- and whole body hyperthermia.

Results The overall response (OR) rate of the 129 stage IV patients was 49.6% with an objective response (ORR) of 31.8%. In 15 stage I-III cancer patients, the overall response (OR) rate and objective response (ORR) were 93%, respectively. The entire treatment was performed as outpatient therapy which was mostly associated with a toxicity of grade 1–2 (24.4 and 14.9%, respectively), including nausea, diarrhea, skin rash and pruritus, and elevation of liver transaminases during the first 24 hours. Only 4,76% of the patients developed grade III and 1,79% grade IV irAEs, such as autoimmune hepatitis, thyroid problems, acute kidney injury and/or diabetes mellitus. There were no signs of late adverse events from this treatment with follow-up greater than 5 years post therapy.

Conclusions In comparison to the commonly known rates of response and side effects in ICI, we were able to show relatively high response rates in parallel with low toxicity profile by the aid of immune response modifiers.

Disclosure Information R. Kleef: None. R. Nagy: None. V. Bacher: None. T. Bakacs: None. T. Lausch: None. D. McKee: None. R. Moss: None. H. Bojar: None. N. Thoennissen: None.

P08.02 BERBERINE-LOADED LIPOSOME FORMULATION ENHANCE THE PHAGOCYTIC ACTIVITY OF LIPOSOMAL IMIQUIMOD TOWARDS COLON CANCER CELL LINES

M Mianowska*, M Zaremba-Czogalla, A Zygmunt, J Gubernator. *Wroclaw University, Wroclaw, Poland*

10.1136/jitc-2020-ITOC7.98

Background Colorectal cancer is the third most commonly diagnosed malignant tumor, taking fourth place in terms of cause of cancer deaths worldwide.¹ Unfortunately, the ability of the immune system to distinguish its own from foreign cells is often limited. One of the overexpressed receptors is receptor CD47 - widely distributed glycoprotein on the cell surface of various kind of tumors. It plays a role as 'don't eat me' signal by binding with receptor SIRP α , presents on the cell surface of macrophages.² Calreticulin, protein occurring on the surface of tumor cells and phagocytes, acts as protein with pro-phagocytic properties. Several natural bioactive substances are predicted to induce immunogenic cell death by translocation calreticulin on the surface of cancer cells which significantly increases the efficiency of their phagocytosis. Moreover, one of the well-known TLR-7 receptor agonists - imiquimod, is involved in phosphorylation of Bruton's tyrosine kinase leading to the appearance of calreticulin on the surface of macrophages, which increases the efficiency of phagocytosis of tumor cells.³ Combination therapy composed of berberine and imiquimod can be highlighted as effective immunotherapy for colon cancer. However, such an approach remains very limited. Liposomes can serve as promising carriers for targeting delivery and controlled release of anti-cancer agents.

Material and Methods Liposomes were prepared by the thin-film hydration method followed by extrusion. Human colon cancer cell line (LS180 I SW620) and human monocytic cell line (THP-1) were used for experiments. Calreticulin was detected by using confocal microscopy.

Results The work presented aimed to develop novel liposomal formulations of berberine and imiquimod which were examined for their efficacy in combination against colorectal cancer cell lines. Liposomal formulations of both compounds were successfully prepared using active loading method with different pH generating agents. All loading methods showed desired characteristics in terms of mean liposome size and polydispersity. The encapsulation efficiency was higher than 95% for almost all used formulations. The *in vitro* study proved cytotoxicity of berberine loaded liposomal formulations on tested colon cancer cell lines. The results of the immunofluorescence staining indicated that the both compounds triggered calreticulin on the cell surface (colon cancer or macrophages).

Conclusions The combination of both substances in the liposomal form may generate a synergistic effect on phagocytosis of colon cancer cells.

REFERENCES

1. Arnold M, Sierra MS, Laversanne M, *et al.* Global patterns and trends in colorectal cancer incidence and mortality. *Gut* 2017;**66**:683–691.
2. Sick E, Jeanne A, Schneider C, Dedieu S, Takeda K, Martiny L. CD47 update: a multifaceted actor in the tumor microenvironment of potential therapeutic interest, *Br J Pharmacol* 2012, **167**(7):1415–30.
3. M. Feng, *et al.*, Macrophages eat cancer cells using their own calreticulin as a guide: Roles of TLR and Btk. *PNAS* 2015;**112**(7):2145–2150.

Disclosure Information M. Mianowska: B. Research Grant (principal investigator, collaborator or consultant and pending grants as well as grants already received); Significant; National Science Center, Poland. M. Zaremba-Czogalla: None. A. Zygmunt: None. J. Gubernator: None.

P08.03 COMBINING PD-1/PD-L1 BLOCKADE AND RANKL INHIBITORS TO TREAT BREAST CANCERS UNRESPONSIVE TO STANDARD THERAPY

C Pilard*, P Roncarati, E Hendrick, A Lebeau, D Bruyère, T Lerho, M Ancion, C Reynders, P Delvenne, M Herfs, P Hubert. *Laboratory of Experimental Pathology, GIGA-Cancer, University of Liege, Liège, Belgium*

10.1136/jitc-2020-ITOC7.99

Background In the past decade, immunotherapy using immune checkpoint inhibitors (especially targeting the PD-1/PD-L1 axis) has been demonstrated as a promising strategy for the treatment of cancers that do not respond to classical chemoradiotherapy. Given that cancer cells have the potential to express many immunosuppressive molecules other than PD-L1, the combination of immune checkpoint inhibitors with other drugs thwarting tumor immunosuppressive microenvironment could represent a promising strategy. Among these immunosuppressive molecules, RANKL, a member of the TNF superfamily, which mainly affects the immune system and bone remodeling, has been shown to be a key factor promoting the progression of breast cancer. In addition, RANKL induces the formation of tolerogenic dendritic cells and Treg cells, which promotes immunotolerance to the tumor.

The aim of this research project is to study the impact of several RANKL inhibitors on triple negative breast cancer and to analyze the efficiency of their association with anti-PD-1/PD-L1 agents.

Materials and Methods We studied RANKL and PD-L1 expression in several murine and human breast cancer cell lines by immunohistochemistry. The secretion of RANKL was analyzed

by ELISA. Inhibitors of RANKL were then tested *in vitro*. We selected several RANKL inhibitors: anti-RANKL antibody, RANK-Fc, Isoliquiritigenin and Gallic acid gallate. The efficacy of these inhibitors was indirectly evaluated with the murine macrophage RAW264.7 cell line which undergoes, in the presence of RANKL, an osteoclast differentiation (TRAP and Cathepsin K expression). The efficacy of RANKL inhibitors was then evaluated, in this model, by RT-qPCR. Apoptosis and proliferation of the cancer cell lines in the presence of the inhibitors were also analyzed.

Results RANKL/PD-L1 expression profile on specimens from each breast cancer subtypes showed that both immunosuppressive molecules are expressed by all breast cancers with a significantly more intense immunoreactivity for triple negative breast cancers. Most of the cell lines expressed both proteins. We found that RANKL is secreted in their extracellular environment. RANKL inhibitors are efficient and will be tested *in vivo*.

Conclusions Several murine triple negative breast cancer cell lines will be sub-cutaneously injected in mice and the efficacy of both RANKL and PD-L1 inhibitors will be evaluated (separately or in combination). The infiltration of tumor microenvironment by different immune cell populations, the presence of metastasis and the tumor growth will be analyzed.

Disclosure Information C. Pilard: None. P. Roncarati: None. E. Hendrick: None. A. Lebeau: None. D. Bruyère: None. T. Lerho: None. M. Ancion: None. C. Reynders: None. P. Delvenne: None. M. Herfs: None. P. Hubert: None.

P08.04 NEOADJUVANT CHEMORADIO THERAPY WITH SEQUENTIAL IPILIMUMAB AND NIVOLUMAB IN RECTAL CANCER (CHINOREC): A PROSPECTIVE RANDOMIZED, OPEN-LABEL, MULTICENTER, PHASE II CLINICAL TRIAL

^{1,2}J Laengle*, ¹I Kuehrer, ¹D Pils, ¹J Kabiljo, ³K Wöran, ³J Stift, ⁴F Herbst, ⁴B Dauser, ⁵M Monschein, ⁵P Razez, ⁶S Haegele, ⁷M Herac, ⁷W Hulla, ⁸C Bitterman, ⁸F Laengle, ⁹D Tamandl, ¹⁰J Widder, ¹⁰R Schmid, ^{1,2}M Bergmann. ¹Division of General Surgery, Department of Surgery, Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria; ²Ludwig Boltzmann Institute Applied Diagnostics, Medical University of Vienna, Vienna, Austria; ³Department of Pathology, Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria; ⁴Department of Surgery, Hospital of St. John of God, Vienna, Austria; ⁵Department of Surgery, Clinic Floridsdorf, Vienna, Austria; ⁶Department of Pathology, Clinic Floridsdorf, Vienna, Austria; ⁷Institute of Pathology, State Hospital Wiener Neustadt, Wiener Neustadt, Austria; ⁸Department of Surgery, State Hospital Wiener Neustadt, Wiener Neustadt, Austria; ⁹Division of General and Pediatric Radiology, Department of Biomedical Imaging and Image-guided Therapy, Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria; ¹⁰Department of Radiotherapy, Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria

10.1136/jitc-2020-ITOC7.100

Background Immune checkpoint inhibitors (ICI), such as ipilimumab (anti-cytotoxic T-lymphocyte-associated protein 4; CTLA-4) or nivolumab (anti-programmed cell death protein 1; PD-1) have been proven to be an effective strategy in solid cancers. Nevertheless, ICI seem not to be effective in microsatellite stable (MSS) tumors, as those potentially lack an immunogenic priming. Radiotherapy is capable to induce an immunogenic cell death (ICD) and subsequently an immunogenic tumor immune microenvironment (TIME). Thus, the pro-inflammatory effect of radiotherapy might restore the susceptibility of MSS tumors to ICI, leading to more

pronounced tumor shrinkage, as well as to an effective anti-tumor immune response.

Material and Methods In total 80 patients with a locally advanced rectal cancer (LARC) will be randomly assigned in a 30:50 ratio, to receive either standard of care (SOC) neoadjuvant chemoradiotherapy alone (CRT; 50 Gy in 2 Gy fractions with capecitabine 1650 mg/m²/d over 25 working days) or concomitant with a single dose of ipilimumab 1 mg/kg on day 7 following sequentially 3 cycles of nivolumab 3 mg/kg Q2W starting on day 14. Patients will undergo surgery within 10 to 12 weeks post CRT. The primary endpoint is safety, tolerability and feasibility assessed by the latest Clavien-Dindo classification of surgical complications and the common terminology criteria of adverse events (CTCAE).

Results ClinicalTrials.gov identifier: NCT04124601. Serial liquid (plasma, serum, peripheral blood mononuclear cells) and tissue biopsies will be taken sequentially before, during and after neoadjuvant therapy. Secondary objectives are radiographic (mrTRG) and pathological (TRG) therapy response. Immune cell infiltrate of resected specimen, as well as genomic, transcriptomic, epigenomic and proteomic pattern of sequential liquid and tissue biopsies will be correlated with therapy response and clinical outcome.

Conclusion This is the first in human study, which uses neoadjuvant CRT in LARC patients with concomitant ipilimumab and nivolumab, applied in a sequential approach. A detailed understanding of therapy induced changes during neoadjuvant CRT with concomitant ICI in a human translation setting will allow the application of radiotherapy as a part of novel immunotherapeutic concept. This is an investigator-initiated trial (IIT), which received a research grant and the study medications from Bristol-Myers Squibb (BMS).

Disclosure Information J. Laengle: B. Research Grant (principal investigator, collaborator or consultant and pending grants as well as grants already received); Significant; IIT, Research Grant & Study Medication from BMS. I. Kuehrer: None. D. Pils: None. J. Kabiljo: None. K. Wöran: None. J. Stift: None. F. Herbst: None. B. Dauser: None. M. Monschein: None. P. Razez: None. S. Haegele: None. M. Herac: None. W. Hulla: None. C. Bitterman: None. F. Laengle: None. D. Tamandl: None. J. Widder: None. R. Schmid: None. M. Bergmann: B. Research Grant (principal investigator, collaborator or consultant and pending grants as well as grants already received); Significant; IIT, Research Grant & Study Medication from BMS.

P09 Young Researchers Session

P09.01 ADOPTIVE CELL THERAPY OF HEMATOLOGICAL MALIGNANCIES USING CYTOKINE-INDUCED KILLER CELLS RETARGETED WITH MONOCLONAL ANTIBODIES

¹A Dalla Pietà*, ¹E Cappuzzello, ¹P Palmerini, ²R Sommaggio, ³G Astori, ³K Chiericato, ⁴O Perbellini, ⁴M Tisi, ⁵C Visco, ⁴M Ruggeri, ^{1,2}A Rosato. ¹Department of Surgery, Oncology and Gastroenterology, Immunology and Oncology Section, University of Padua, Padua, Italy; ²Veneto Institute of Oncology IOV – IRCCS, Padua, Italy; ³Advanced Cellular Therapy Laboratory, Hematology Department, San Bortolo Hospital, Vicenza, Italy; ⁴Hematology Department, San Bortolo Hospital, Vicenza, Italy; ⁵Department of Medicine, Section of Hematology, University of Verona, Verona, Italy

10.1136/jitc-2020-ITOC7.101